Hypertension Labeling Should Say Classes Are All Effective, But Unequally So
Executive Summary
Antihypertensive drug class labeling for cardiovascular outcomes should specify that some classes of agents are more effective at reducing such events than others, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said
You may also be interested in...
Comparative Research Needs New Approach To Answer Real-Life Questions
To get the most out of the new funding for research on the comparative effectiveness of health care products and services, research needs to go in new directions so that it can answer real-world questions, two former CMS officials said at a recent forum at the American Enterprise Institute
Comparative Research Needs New Approach To Answer Real-Life Questions
To get the most out of the new funding for research on the comparative effectiveness of health care products and services, research needs to go in new directions so that it can answer real-world questions, two former CMS officials said at a recent forum at the American Enterprise Institute
FDA Advisory Committee Conflict Policy Takes A Toll; Chairs Plan Response
Cardiovascular & Renal Drugs Advisory Committee Chair William Hiatt plans to write an editorial concerning the need for a more transparent conflict of interest policy for panel members